Skip to main content

Transforming the understanding
and treatment of mental illnesses.

AIDS-related Funding Opportunity Announcements (FOAs)

NIMH FOAs

NOT-MH-20-013: Notice of Special Interest (NOSI): Mental Health Comorbidities in HIV Prevention and Treatment

NOT-MH-20-019: Notice of Special Interest (NOSI): Strengthening the HIV Prevention Continuum

NOT-MH-20-020: Notice of Special Interest: Stigma or Other Social Determinants of Health (SDOH) in HIV Prevention and Treatment

NOT-MH-20-023: Notice of Special Interest (NOSI): Strengthening the HIV Care Continuum

NOT-MH-20-024: Notice of Special Interest (NOSI): Implementation Science to Advance the United States HIV Prevention and Treatment Goals and the Global HIV Prevention and Treatment Targets

NOT-MH-20-035: Notice of Special Interest (NOSI): Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults

NOT-MH-21-105: Notice of Special Interest (NOSI): Advancing Health Communication Research on HIV Prevention, Treatment, and Cure

NOT-MH-22-095: Notice of Special Interest (NOSI): NIMH Priorities on Research on Aggression and Violence Against Others

PA-20-144: Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)

PA-20-141: Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (R34 Clinical Trial Optional)

PA-20-145: Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)

PAR-20-307: Developmental AIDS Research Centers on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)

PAR-21-228: NIMH Research Education Mentoring Program for HIV/AIDS Researchers (R25 Clinical Trial Not Allowed)

PAR-20-308: AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional) 

PAR-20-151: Eradication of HIV-1 from Central Nervous system Reservoirs (R01 Clinical Trial Not Allowed)

PAR-20-149: HIV Infection of the Central Nervous System (R01 Clinical Trial Not Allowed)

RFA-MH-22-170: Advancing communication strategies to support future HIV vaccine use (R01 Clinical Trial Optional)

RFA-MH-22-171: Advancing communication strategies to support future HIV vaccine use (R21 Clinical Trial Optional)

Co-Sponsored FOAs

NOT-AI-21-054: Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV

NOT-AI-21-057: Notice of Special Interest (NOSI) HIV/AIDS in the Era of COVID-19: When Pandemics Collide

NOT-CA-22-037: Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research

NOT-OD-22-069: Notice of Special Interest (NOSI): Support for existing data repositories to align with FAIR and TRUST principles and evaluate usage, utility, and impact

NOT-OD-22-065: Notice of Special Interest (NOSI): Administrative Supplements for Advancing the Ethical Development and Use of AI/ML in Biomedical and Behavioral Sciences

NOT-OD-22-067: Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations to Improve the AI/ML-Readiness of NIH-Supported Data

NOT-OD-22-068: Notice of Special Interest (NOSI): Administrative Supplements to Support Enhancement of Software Tools for Open Science

NOT-DA-21-060: Notice of Special Interest (NOSI): Reducing Stigma Related to Drug Use in Human Service Settings

NOT-OD-21-100: Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health

NOT-MD-22-006: Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities

NOT-AI-21-011: Notice of Special Interest (NOSI): Secondary Analysis of Existing Datasets for Advancing Immune-mediated and Infectious Disease Research

NOT-CA-22-037: Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research

NOT-MH-22-095: Notice of Special Interest: NIMH Priorities on Aggression and Violence Against Others

PAR-21-303: Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional)

PAR-21-068: Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)

PAR-20-036: Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional) 

PAR-21-344: Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 - Clinical Trial Optional)

PAR-21-297: Novel Systemic Options for Young Adults under the tab PA-Joint; Multipurpose Prevention Technology 

PAR-21-070: Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed)

PAR-21-297: Multipurpose Prevention Technology: Novel Systemic Options for Young Adults